An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities.

Based on gene expression profiles, diffuse large B cell lymphoma (DLBCL) is sub-divided into germinal center B cell-like (GCB) and activated B cell-like (ABC) DLBCL. Two of the most common genomic aberrations in ABC-DLBCL are mutations in MYD88, as well as BCL2 copy number gains. Here, we employ immune phenotyping, RNA-Seq and whole exome sequencing to characterize a Myd88 and Bcl2-driven mouse model of ABC-DLBCL. We show that this model resembles features of human ABC-DLBCL. We further demonstrate an actionable dependence of our murine ABC-DLBCL model on BCL2. This BCL2 dependence was also detectable in human ABC-DLBCL cell lines. Moreover, human ABC-DLBCLs displayed increased PD-L1 expression, compared to GCB-DLBCL. In vivo experiments in our ABC-DLBCL model showed that combined venetoclax and RMP1-14 significantly increased the overall survival of lymphoma bearing animals, indicating that this combination may be a viable option for selected human ABC-DLBCL cases harboring MYD88 and BCL2 aberrations.

[1]  L. Cascione,et al.  Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. , 2020, Blood advances.

[2]  Gennady Korotkevich,et al.  Fast gene set enrichment analysis , 2019, bioRxiv.

[3]  L. Staudt,et al.  Pathogenic B‐cell receptor signaling in lymphoid malignancies: New insights to improve treatment , 2019, Immunological reviews.

[4]  J. Martinez-Climent,et al.  PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. , 2019, Blood.

[5]  V. Kuchroo,et al.  Tim-3: A co-receptor with diverse roles in T cell exhaustion and tolerance. , 2019, Seminars in immunology.

[6]  F. Westermann,et al.  A mechanistic classification of clinical phenotypes in neuroblastoma , 2018, Science.

[7]  R. Büttner,et al.  The Cdkn1aSUPER Mouse as a Tool to Study p53-Mediated Tumor Suppression. , 2018, Cell reports.

[8]  H. Reinhardt,et al.  Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities , 2018, Cancer Immunology, Immunotherapy.

[9]  Y. Okamoto,et al.  Crucial role of CD69 in anti-tumor immunity through regulating the exhaustion of tumor-infiltrating T cells , 2018, International immunology.

[10]  H. Gohlke,et al.  Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. , 2018, Blood.

[11]  L. Staudt,et al.  A Multiprotein Supercomplex Controlling Oncogenic Signaling in Lymphoma , 2018, Nature.

[12]  Mark D. Robinson,et al.  Compensation of Signal Spillover in Suspension and Imaging Mass Cytometry , 2018, Cell systems.

[13]  Stefano Monti,et al.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.

[14]  Michael L. Wang,et al.  Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas , 2018, Clinical Cancer Research.

[15]  Roland Schmitz,et al.  Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma , 2018, The New England journal of medicine.

[16]  Simon C Watkins,et al.  4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses , 2018, The Journal of experimental medicine.

[17]  W. Shi,et al.  Transcription Factor IRF4 Promotes CD8+ T Cell Exhaustion and Limits the Development of Memory‐like T Cells during Chronic Infection , 2017, Immunity.

[18]  Andrzej K. Oleś,et al.  Drug-perturbation-based stratification of blood cancer , 2017, The Journal of Clinical Investigation.

[19]  W. Kim.  Faculty of 1000 evaluation for The 2016 revision of the World Health Organization classification of lymphoid neoplasms. , 2017 .

[20]  D. Dunson,et al.  Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma , 2017, Cell.

[21]  T. Gooley,et al.  Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas. , 2017, Cancer research.

[22]  I. Frazer,et al.  Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity , 2017, Cell Death & Disease.

[23]  J. Chavez,et al.  The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: The future is now. , 2017, Critical reviews in oncology/hematology.

[24]  Geet Duggal,et al.  Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference , 2017, Nature Methods.

[25]  Jason B. Williams,et al.  The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment , 2017, The Journal of experimental medicine.

[26]  T. Kipps,et al.  Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Millenson,et al.  Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Tiemann,et al.  [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study]. , 2016, Der Pathologe.

[29]  Evgeny S. Egorov,et al.  High-quality full-length immunoglobulin profiling with unique molecular barcoding , 2016, Nature Protocols.

[30]  Kui Wu,et al.  Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. , 2016, Blood.

[31]  L. Staudt,et al.  LYMPHOID NEOPLASIA B-cell – speci fi c conditional expression of Myd88 p.L252P leads to the development of diffuse large B-cell lymphoma in mice by Sequencing Project , 2016 .

[32]  A. Oxenius,et al.  Tumor-necrosis factor impairs CD4+ T cell–mediated immunological control in chronic viral infection , 2016, Nature Immunology.

[33]  C. Jiang,et al.  Regulation of PD-L1: a novel role of pro-survival signalling in cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  L. Staudt,et al.  Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens , 2015, Proceedings of the National Academy of Sciences.

[35]  K. Basso,et al.  Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis , 2015, Nature Medicine.

[36]  Mikhail Shugay,et al.  MiXCR: software for comprehensive adaptive immunity profiling , 2015, Nature Methods.

[37]  K. Basso,et al.  Germinal centres and B cell lymphomagenesis , 2015, Nature Reviews Immunology.

[38]  M. Reth,et al.  B cell activation involves nanoscale receptor reorganizations and inside-out signaling by Syk , 2014, eLife.

[39]  Mikhail Shugay,et al.  Towards error-free profiling of immune repertoires , 2014, Nature Methods.

[40]  Krister Wennerberg,et al.  Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. , 2013, Cancer discovery.

[41]  N. Gray,et al.  A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. , 2013, Blood.

[42]  A. Letai,et al.  BH3 profiling in whole cells by fluorimeter or FACS. , 2013, Methods.

[43]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[44]  M Ladetto,et al.  Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  R. Siebert,et al.  Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. , 2012, Cancer cell.

[46]  L. Staudt,et al.  Pathogenesis of human B cell lymphomas. , 2012, Annual review of immunology.

[47]  P. Casali,et al.  BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-κB pathway , 2012, Nature Communications.

[48]  A. López-Guillermo,et al.  CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. , 2011, The Lancet. Oncology.

[49]  Joseph M. Connors,et al.  Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.

[50]  N. Schmitz,et al.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Vilppu J Tuominen,et al.  ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 , 2010, Breast Cancer Research.

[52]  A. Zajac,et al.  T‐cell exhaustion: characteristics, causes and conversion , 2010, Immunology.

[53]  G. Salles,et al.  Plasma TNF-α and IL-10 Level-Based Prognostic Model Predicts Outcome of Patients with Diffuse Large B-Cell Lymphoma in Different Risk Groups Defined by the International Prognostic Index , 2010, Archivum Immunologiae et Therapiae Experimentalis.

[54]  Luis Serrano,et al.  Correlation of mRNA and protein in complex biological samples , 2009, FEBS letters.

[55]  E. Birney,et al.  Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt , 2009, Nature Protocols.

[56]  Carolina Wählby,et al.  BlobFinder, a tool for fluorescence microscopy image cytometry , 2009, Comput. Methods Programs Biomed..

[57]  L. Staudt,et al.  Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.

[58]  U. Landegren,et al.  Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. , 2008, Methods.

[59]  Markus Loeffler,et al.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.

[60]  D. Getnet,et al.  LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. , 2007, The Journal of clinical investigation.

[61]  A. Letai,et al.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. , 2007, Cancer cell.

[62]  B. Quesnel,et al.  Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. , 2007, Blood.

[63]  G. Kelsoe,et al.  T-Independent Activation-Induced Cytidine Deaminase Expression, Class-Switch Recombination, and Antibody Production by Immature/Transitional 1 B Cells1 , 2007, The Journal of Immunology.

[64]  A. Jegerlehner,et al.  TLR9 Signaling in B Cells Determines Class Switch Recombination to IgG2a , 2007, The Journal of Immunology.

[65]  A. Marshak‐Rothstein.  Toll-like receptors in systemic autoimmune disease , 2006, Nature Reviews Immunology.

[66]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[67]  S. Akira,et al.  RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement , 2005, The Journal of experimental medicine.

[68]  F. Triebel,et al.  The negative regulatory function of the lymphocyte‐activation gene‐3 co‐receptor (CD223) on human T cells , 2005, Immunology.

[69]  J. Whitton,et al.  Interferon-γ acts directly on CD8+ T cells to increase their abundance during virus infection , 2005, The Journal of experimental medicine.

[70]  B. He,et al.  CpG DNA Induces IgG Class Switch DNA Recombination by Activating Human B Cells through an Innate Pathway That Requires TLR9 and Cooperates with IL-101 , 2004, The Journal of Immunology.

[71]  M. Arias,et al.  Inhibition of B Cell Death Causes the Development of an IgA Nephropathy in (New Zealand White × C57BL/6)F1-bcl-2 Transgenic Mice1 , 2004, The Journal of Immunology.

[72]  A. Zelenetz,et al.  Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. , 2004, Blood.

[73]  S. Horning,et al.  Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. , 2004, Blood.

[74]  M. Shlomchik,et al.  Activation of autoreactive B cells by CpG dsDNA. , 2003, Immunity.

[75]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[76]  M. Shlomchik,et al.  Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors , 2002, Nature.

[77]  M. Shlomchik,et al.  Immune Complexes Present in the Sera of Autoimmune Mice Activate Rheumatoid Factor B Cells1 , 2000, The Journal of Immunology.

[78]  J. Schlessinger,et al.  Absence of marginal zone B cells in Pyk-2–deficient mice defines their role in the humoral response , 2000, Nature Immunology.

[79]  M. Madaio,et al.  The origin of anti-nuclear antibodies in bcl-2 transgenic mice. , 2000, International immunology.

[80]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[81]  B. Diamond,et al.  Bcl‐2 leads to expression of anti‐DNA B cells but no nephritis: a model for a clinical subset , 1999, European journal of immunology.

[82]  T. Manser,et al.  Bcl-2 obstructs negative selection of autoreactive, hypermutated antibody V regions during memory B cell development. , 1998, Immunity.

[83]  H. Mcdevitt,et al.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[84]  K. Rajewsky,et al.  B lymphocyte-specific, Cre-mediated mutagenesis in mice. , 1997, Nucleic acids research.

[85]  R. Paxton,et al.  IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. , 1995, Journal of immunology.

[86]  T. Honjo,et al.  The bcl-2 gene product inhibits clonal deletion of self-reactive B lymphocytes in the periphery but not in the bone marrow , 1993, The Journal of experimental medicine.

[87]  D. Vaux,et al.  Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[88]  J. Hershman,et al.  Characterization of tumor necrosis factor-alpha receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin. , 1989, Endocrinology.

[89]  W. Shi,et al.  Transcription Factor IRF 4 Promotes CD 8 + T Cell Exhaustion and Limits the Development of Memory-like T Cells during Chronic Infection Graphical , 2019 .

[90]  T. Kipps,et al.  Phase I First-inHuman Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma , 2017 .

[91]  A. Rosenwald,et al.  conditional expression of Myd 88 ( p . L 252 P ) leads to the development of diffuse large B cell lymphoma in mice , 2017 .

[92]  J. Cerhan,et al.  Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. , 2014, Journal of the National Cancer Institute. Monographs.

[93]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[94]  Theodore R Holford,et al.  Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. , 2006, The Lancet. Oncology.

[95]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[96]  D. Kunz,et al.  Linkage disequilibrium between tumor necrosis factor (TNF)-alpha-308 G/A promoter and TNF-beta NcoI polymorphisms: Association with TNF-alpha response of granulocytes to endotoxin stimulation. , 2003, Critical care medicine.

[97]  T. Manser,et al.  Enforced Expression of Bcl-2 Selectively Perturbs Negative Selection of Dual Reactive Antibodies , 2001, Developmental immunology.

[98]  A. Peña,et al.  Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. , 1996, Scandinavian journal of immunology.

[99]  C. Snapper,et al.  T cell-independent antigens type 2. , 1995, Annual review of immunology.

[100]  R. Thorpe,et al.  Human B cell proliferation is stimulated by interleukin 2. , 1985, Immunology letters.

[101]  R. Schwartz,et al.  Leukemia and auto-immunization- some possible relationships. , 1959, Blood.